00:52

Describing the World's Largest Human Challenge Unit

03:38

Chief Scientific Officer on Human Challenge Trials & Canary Wharf State-of-the-Art facility

02:11

Director of Clinical Operations on hVIVO's State-of-the-Art Facility in Canary Wharf

04:01

hVIVO at Canary Wharf - Yamin 'Mo' Khan

02:13:12

Capital Markets Day 2024

01:34

Opening of the World's Largest Human Challenge Trial Unit

02:56

Canary Wharf Facilities Walk Through Tour

02:58

Timeline Video hVIVO

04:10

hVIVO Joining the Life Science Hub at Canary Wharf

05:26

Dr Andrew Catchpole on Omicron BA.5 Characterisation Study

02:52

Laboratory Team Leader at hVIVO

02:15

Year in Review 2023

41:45

Ask the Experts: A Deep Dive Into Human Challenge Trials

02:55

Associate Medical Director Role at hVIVO

04:08

hVIVO Canary Wharf Facilities - Adam French

02:26

hVIVO Careers - Fueling Scientific Research

03:11

Developing an Influenza B Human Challenge Model

01:51

VP of Clinical Operations on hVIVO's new Facility

05:36

hVIVO to Develop hMPV Human Challenge Model

48:23

Human Challenge Trials: Supporting the development of ‘next generation’ COVID-19 Vaccines

04:34

hVIVO at World Vaccine Congress Washington 2023

03:26

Director of Business Development Egle Payvde Discusses BioEurope Spring Event

02:23

Venn Life Sciences new offices at Leiden BioScience Park

07:14

hVIVO Omicron Human Challenge Model

05:57

Venn Life Sciences €3.2m Contract Win with Global Pharma Company

02:11

Year in Review 2022 - hVIVO Group

04:37

CEO Yamin 'Mo' Khan on Name Change to hVIVO plc

02:45

Lab Accreditation Awarded to hVIVO

04:30

Alex Mann discusses hVIVO's new Influenza contract - BRR Media

03:19

£6.2m Influenza human challenge study contract - BRR Media

04:07

hVIVO's £7.2m RSV Human Challenge Model Contract

06:04

hVIVO £14.7m Challenge virus manufacturing contract for top 5 global pharmaceutical client

05:20

Chief Scientific Officer on Influenza Challenge Study contract Win

05:43

Open Orphan's CEO on hVIVO's first ever Phase II field study site study awarded

02:58

Chief Scientific Officer, Dr Andrew Catchpole, discusses how hVIVO manufacture challenge agents

04:52

New Facilities on Plumbers Row - Open Orphan Group

05:11

CEO Yamin 'Mo' Khan on peer review of World's 1st COVID-19 Characterisation Study

03:51

Andrew Catchpole on the world’s first COVID-19 characterisation study have been peer reviewed

03:45

CEO Yamin 'Mo' Khan on £5m RSV Challenge Study Contract

06:20

Volunteer Recruitment & Laboratory Facilities Expansion - Robin Rogiers & BRR Media

04:24

CEO Appointment at Open Orphan

08:06

Adrian Wildfire on hVIVO STRiVE Project

06:06

Chief Scientific Officer Andrew Catchpole on the world’s first COVID-19 Characterisation Study

03:56

Executive Chairman Cathal Friel on The world’s first COVID-19 Characterisation Study

09:00

Adrian Wildfire hVIVO Malaria Challenge Agent - BRR Media

02:43

BRR Interview Cathal Friel on Malaria Human challenge agent

02:01

Year in Review 2021 - Open Orphan

02:58

$13.4m Influenza HCS contract win

57:01

The World's First Covid-19 Human Challenge Trial: The Regulatory Challenges - TOPRA Presentation

05:59

Cathal Friel discusses the H1 2021 Interim Results & £5.7m influenza human challenge contract

04:57

Cathal Friel and BRR Media Discuss £8.1m Asthma Human Challenge Study Contract Win

02:10

FluCamp Hotel Quarantine Facility - Bedroom Tour

01:59

Alle zaken op een rijtje - Venn Life Sciences

02:37

Open Orphan state of the art QMB facility

00:35

hVIVO Whitechapel Clinic

00:32

hVIVO's new volunteer screening centres

01:19

hVIVO secure MHRA approval to start Codagenix COVID-19 Phase I Vaccine Trial - BRR Media

03:22

Landmark UK Government Deal

05:20

Open Orphan Dual Business Firing on All Four Cylinders

06:14

Open Orphan Interim Results Interview with BRR Media